# **CE Information**

VOL 5 | SUPPL 1 | MAY/JUN 2014



Provided by the Meniscus Educational Institute and the Journal of the Advanced Practitioner in Oncology



## Collaborative Practice Enhances Supportive Care in Cancer: Chemotherapy-Induced Nausea and Vomiting

Release date: May 22, 2014 • Expiration date: May 22, 2015 • Estimated time to complete activity: 2 hours

This activity is supported by an unrestricted educational grant from Heron Therapeutics (formerly AP Pharma).

#### Meniscus Educational Institute

18 Elizabeth Street, Suite 300 West Conshohocken, PA 19428-2935 Voice: 610-834-1810 Fax: 610-834-8856 E-mail: email@meniscus.com Internet: www.meniscus.com

#### Journal of the Advanced Practitioner in Oncology

Published by Harborside Press, LLC 37 Main Street Cold Spring Harbor, NY 11724 Voice: 631-692-0800 Fax: 631-692-0805 E-mail: jeannine@harborsidepress.com Internet: www.harborsidepress.com

© 2014, Meniscus Educational Institute. All rights reserved.

### Faculty

Sally Barbour, PharmD, BCOP, CPP, Duke University Medical Center Teresa Scardino, RPA-C, MPAS, Memorial Sloan Kettering Cancer Center Rita Wickham, PhD, RN, AOCN<sup>®</sup>, Rush University College of Nursing (Adjunct Faculty)

### **Activity Rationale and Purpose**

A team of an oncology advanced practice nurse, a physician assistant, and a pharmacist discuss the importance of the interprofessional approach to supportive care in patients who may experience chemotherapy-induced nausea and vomiting (CINV). The authors use a case study to illustrate models collaborative care; discuss physiologic mechanisms of CINV, principles of antiemetic prevention and management, and current standard-of-care antiemetic management; review and formulate pre- and post-chemotherapy assessment models that stress continuation throughout the period of delayed and breakthrough CINV and integrate self-care measures. In addition to outlining limitations of currently available evidence-based antiemetic therapies, the authors review pipeline approaches to CINV treatment and end with collaborative identification of other important measurable outcomes to the efficacy of antiemetic therapies.

## **Intended Audience**

The program's target audience consists of physicians, advanced practice nurses (nurse practitioners [NPs] and clinical nurse specialists [CNSs]), physician assistants, and pharmacists who focus on clinical practice and/or education in oncology or hematology care settings.

## **Learning Objectives**

- 1. Review physiologic, drug, and patient factors as they relate to risk calculation and assessment of chemotherapyinduced nausea and vomiting (CINV)
- 2. Discuss current standard-of-care interventions for moderately and highly emetogenic chemotherapy (MEC and HEC) and clinical or economic factors that could limit best antiemetic use

2

- 3. Summarize drugs and products in development that aim to enhance CINV prevention and management
- 4. Engage in a collaborative discussion to develop strategies to maximize CINV management



## **Continuing Education**

Statement of Credit-Participants who successfully complete this activity (including the submission of the post-test and evaluation form with an e-mail address) will receive a statement of credit via e-mail.



**Physicians**. The Meniscus Educational Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Meniscus Educational Institute designates this live activity (271.006-1407-MJ) for a maximum of 2 AMA PRA *Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Nurses. This activity (271.006-1407-NJ) for 2.0 contact hours is provided by the Meniscus Educational Institute. The Meniscus Educational Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Accreditation refers to recognition of educational activities only and does not imply approval or endorsement by the Meniscus Educational Institute or the American Nurses Credentialing Center's Commission on Accreditation of any product mentioned.

Provider approved by the California Board of Registered Nursing, Provider No. 13164, for 2 contact hours.



Pharmacists. The knowledge-based accredited education lectures are intended for pharmacists involved in the care of cancer patients. This educational activity is sponsored by the Meniscus Educational Institute. The Meniscus Educational Institute is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. The ACPE Universal Activity Number assigned to this program, for 2 contact hours, is 0429-9999-14-007-H04-P.

Important Notice Concerning Pharmacy Credits: As of January 1, 2013, a central electronic repository for CPE information will be implemented nationally to enable state boards of pharmacy to efficiently verify CE completion. During registration for any ACPE-accredited program, you will be required to provide a valid NABP e-profile ID (e-PID) number, along with your date of birth (as "MM/DD"), in order to receive credit. No CPE credit will be issued or honored by paper certificate for programs attended after January 1st; however, you may receive, at the discretion of your CPE provider, a courtesy receipt of credit for informational purposes only. Licensed pharmacists and pharmacy technicians can obtain an e-PID number by registering with the CPE Monitor through the NABP website at www.nabp.net.

## **Financial Disclosures**

All individuals in positions to control the content of this program (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Meniscus Educational Institute has identified and resolved all conflicts of interst in accordance with the MEI policies and procedures. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.

3

#### Faculty

Sally Barbour, PharmD, BCOP, CPP, has nothing to disclose. Teresa Scardino, RPA-C, MPAS, has nothing to disclose. Rita Wickham, PhD, RN, AOCN<sup>®</sup>, has served on speakers bureaus for Genentech.

#### **Content Reviewers**

Pamela Hallquist Viale, RN, MS, CNS, ANP, has nothing to disclose. **Claudine Kiffer** has nothing to disclose.

#### **Nurse Planner**

Pamela Hallquist Viale, RN, MS, CNS, ANP, has nothing to disclose.

#### **Education Committee and Planners**

Jeannine Coronna has nothing to disclose. Terry Logan, CCMEP, has nothing to disclose. Molly Thompson has nothing to disclose. Susan Reckling has nothing to disclose. Joseph Cupola has nothing to disclose. Pamela Hallquist Viale, RN, MS, CNS, ANP, has nothing to disclose.

#### **Pilot Study Reviewers**

Glenn Bingle, MD, has nothing to disclose. Karen Abbas, MS, RN, AOCN<sup>®</sup>, has nothing to disclose. Christopher J. Campen, PharmD, BCPS, BCOP, has nothing to disclose.

# **CE Information**

VOL 5 | SUPPL 1 | MAY/JUN 2014

## Disclaimer

This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Meniscus Educational Institute educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.

The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Meniscus Educational Institute of any specific therapeutics or approaches to diagnosis or patient management.

## **Product Disclosure**

This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.

There is no fee for participating in this activity.



Meniscus Educational Institute 18 Elizabeth Street, Suite 300 West Conshohocken, PA 19428-2935 Voice Mail: 610-834-1810 Fax: 610-834-8856 Internet: info@meniscusedu.com

The Meniscus Educational Institute has a full complement of CE offerings on our Web site, www.meniscus.com.

# How to Earn Credit

To access the learning assessment and evaluation form online, visit www.meniscusce.com

**Statement of Credit:** Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment and complete and submit the evaluation form with an E-mail address) will be able to download a statement of credit.

4